To evaluate the possible associations between AGER (rs1051993, rs2070600) and ALDH2 (rs671) gene polymorphisms with nonproliferative (NPDR) and proliferative (PDR) diabetic retinopathy, in a well-defined Greek population.
Materials
66 NPDR patients and 57 PDR patients participated in our study, along with 156 age- and gender-matched healthy-control subjects (CL). All the participants underwent a complete ophthalmological examination, while clinical and demographic data were collected. Furthermore, they were genotyped for the studied polymorphisms.
Results
No significant differences were detected among the studied groups regarding the participants’ age and gender status. We found that the ALDH2 AA genotype was significantly more frequent in PDR patients than in CL (p = 0.014). Furthermore, between NPDR and PDR groups, the AGER rs1051993 GT and TT genotype frequencies were significantly elevated in PDR patients (p < 0.0001 and 0.04, respectively). Moreover, we demonstrated that the heterozygous GT genotype in DR patients is accompanied by 71.11 times higher risk of developing PDR (OR = 71.11: 95% CI- 4.14–1215.2), while the homozygous TT genotype is associated with 12.71 times elevated risk for PDR development (OR = 12.71: 95% CI- 0.63–254.1).
Conclusions
We documented that the ALDH2 AA and AGER rs1051993 GT and TT genotypes were observed significantly more frequently in PDR Greek diabetic patients. Our findings also support the genetic theory, suggesting that heritability is significantly implicated in the development of DR, providing additional evidence in the understanding of DR pathogenesis.
YauJWRogersSLKawasakiR, et al.Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care2012; 35: 556–564.
2.
LeeRWongTYSabanayagamC. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond)2015; 2: 17.
3.
SiasosGGouliopoulosNMoschosMM, et al.Role of endothelial dysfunction and arterial stiffness in the development of diabetic retinopathy. Diabetes Care2015; 38: 9–10.
4.
KleinRKleinBEMossSE,et al.The Wisconsin epidemiologic study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol1994; 112: 1217–1228.
5.
NairBMViswanathanVSnehalathaC,et al.Flow mediated dilatation and carotid intimal media thickness in South Indian type 2 diabetic subjects. Diabetes Res Clin Pract2004; 65: 13–19.
6.
AntonettiDAKleinRGardnerTW. Diabetic retinopathy. N Engl J Med2012; 366: 1227–1239.
7.
TingDSCheungGCWongTY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol2016; 44: 260–277.
8.
KleinRKleinBEMossSE. Is obesity related to microvascular and macrovascular complications in diabetes? The Wisconsin epidemiologic study of diabetic retinopathy. Arch Intern Med1997; 157: 650–656.
9.
RamanRRaniPKKulothunganV,et al.Influence of serum lipids on clinically significant versus nonclinically significant macular edema: sN-DREAMS report number 13. Ophthalmology2010; 117: 766–772.
10.
GouliopoulosNAntonopoulosASSiasosG, et al.Macrovascular function indices for the prediction of diabetic retinopathy development in patients with type 2 diabetes. Eur J Prev Cardiol2017; 24: 1405–1407.
11.
AntonopoulosASSiasosGOikonomouE, et al.Arterial stiffness and microvascular disease in type 2 diabetes. Eur J Clin Invest2021; 51: e13380.
12.
GouliopoulosNSKalogeropoulosCLavarisA, et al.Association of serum inflammatory markers and diabetic retinopathy: a review of literature. Eur Rev Med Pharmacol Sci2018; 22: 7113–7128.
13.
ArnoldERiveraJCThebaultS, et al.High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins. Diabetes2010; 59: 3192–3197.
14.
KolliaCAntonopoulosASSiasosG, et al.Associations between adiponectin gene variability, proinflammatory and angiogenetic markers: implications for microvascular disease development in type 2 diabetes mellitus?Curr Vasc Pharmacol2019; 17: 204–208.
15.
LookerHCNelsonRGChewE, et al.Genome-wide linkage analyses to identify loci for diabetic retinopathy. Diabetes2007; 56: 1160–1166.
16.
HietalaKForsblomCSummanenP,et al.Heritability of proliferative diabetic retinopathy. Diabetes. 2008; 57: 2176–2180.
17.
ArarNHFreedmanBIAdlerSG, et al.Heritability of the severity of diabetic retinopathy: the FIND-eye study. Invest Ophthalmol Vis Sci2008; 49: 3839–3845.
18.
DonaghueKCMarganSHChanAK, et al.The association of aldose reductase gene (AKR1B1) polymorphisms with diabetic neuropathy in adolescents. Diabet Med2005; 22: 1315–1320.
19.
NakamuraSIwasakiNFunatsuH,et al.Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol2009; 247: 21–26.
20.
GouliopoulosNSiasosGOikonomouD, et al.The association of T786C and G894T polymorphisms of eNOS gene with diabetic retinopathy in Greece. Eur J Ophthalmol2021; 2021: 11206721211054724. (Epub ahead of print).
21.
ChenYHuangHZhouJ, et al.Polymorphism of the endothelial nitric oxide synthase gene is associated with diabetic retinopathy in a cohort of West Africans. Mol Vis2007; 13: 2142–2147.
22.
BalasubbuSSundaresanPRajendranA, et al.Association analysis of nine candidate gene polymorphisms in Indian patients with type 2 diabetic retinopathy. BMC Med Genet2010; 11: 158.
23.
MoritaKSaruwatariJMiyagawaH, et al.Association between aldehyde dehydrogenase 2 polymorphisms and the incidence of diabetic retinopathy among Japanese subjects with type 2 diabetes mellitus. Cardiovasc Diabetol2013; 12: 132.
24.
GouliopoulosNSiasosGBouratzisN, et al.Polymorphism analysis of ADIPOQ gene in Greek patients with diabetic retinopathy. Ophthalmic Genet2021; 13: 1–6.
25.
SikkaRRainaPMatharooK, et al.TNF-α (g.-308G.A) and ADIPOQ (g.+45T.G) gene polymorphisms in type 2 diabetes and microvascular complications in the region of Punjab (North-West India). Curr Eye Res2014; 39: 1042–1051.
26.
LiYWuQHJiaoML, et al.Gene-environment interaction between adiponectin gene polymorphisms and environmental factors on the risk of diabetic retinopathy. J Diabetes Investig2015; 6: 56–66.
27.
WangJYangMMLiYB,et al.Association of CFH and CFB gene polymorphisms with retinopathy in type 2 diabetic patients. Mediators Inflamm2013; 2013: 748435.
28.
AntonopoulosASSiasosGKonsolaT, et al.Arterial wall elastic properties and endothelial dysfunction in the diabetic foot syndrome in patients with type 2 diabetes. Diabetes Care2015; 38: e180–e181.
29.
KonsolaTSiasosGAntonopoulosAS, et al.The impact of T786C and G894T polymorphisms of eNOS on vascular endothelial growth factor serum levels in type 2 diabetes patients. Int J Cardiol2016; 222: 155–156.
30.
SunLZhangYXiongY. GSTM1 and GSTT1 null genotype and diabetic retinopathy: a meta-analysis. Int J Clin Exp Med2015; 8: 1677–1683.
31.
YangXDengYGuH, et al.Candidate gene association study for diabetic retinopathy in Chinese patients with type 2 diabetes. Mol Vis2014; 20: 200–214.
32.
VinitaKSripriyaSPrathibaK, et al. ICAM-1 K469E polymorphism is a genetic determinant for the clinical risk factors of T2D subjects with retinopathy in Indians: a population-based case-control study. BMJ Open2012; 2: e001036. pii.
33.
SuXChenXLiuL,et al.Intracellular adhesion molecule-1 K469E gene polymorphism and risk of diabetic microvascular complications: a meta-analysis. PLoS One2013; 8: e69940.
34.
SunHCongXSunR,et al.Association between the ICAM-1 K469E polymorphism and diabetic retinopathy in type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract2014; 104: e46–e49.
35.
HeldTKWeihuaXYuanL,et al.Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1. Infect Immun1999; 67: 206–212.
36.
PaineSKBasuAMondalLK, et al.Association of vascular endothelial growth factor, transforming growth factor beta, and interferon gamma gene polymorphisms with proliferative diabetic retinopathy in patients with type 2 diabetes. Mol Vis2012; 18: 2749–2757.
37.
PaineSKSenAChoudhuriS, et al.Association of tumor necrosis factor α, interleukin 6, and interleukin 10 promoter polymorphism with proliferative diabetic retinopathy in type 2 diabetic subjects. Retina2012; 32: 1197–1203.
38.
JeonHJChoiHJParkBH,et al.Association of monocyte chemoattractant protein-1 (MCP-1) 2518A/G polymorphism with proliferative diabetic retinopathy in Korean type 2 diabetes. Yonsei Med J2013; 54: 621–625.
39.
ZhangTPangCLiN,et al.Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis. BMC Med2013; 11: 1.
40.
XuKLiuXYangF, et al.PAI-1-675 4G/5G polymorphism in association with diabetes and diabetic complications susceptibility: a meta-analysis study. PLoS One2013; 8: e79150.
41.
LiuLJiaoJWangY, et al.TGF-beta1 gene polymorphism in association with diabetic retinopathy susceptibility: a systematic review and meta-analysis. PLoS One2014; 9: e94160.
42.
SestiLFCrispimDCananiLH, et al.The -308G.a polymorphism of the TNF gene is associated with proliferative diabetic retinopathy in Caucasian Brazilians with type 2 diabetes. Invest Ophthalmol Vis Sci2015; 56: 1184–1190.
43.
BaynesJWThorpeSR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med2000; 28: 1708–1716.
44.
KalousovaMZimaTTesarV,et al.Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res2005; 579: 37–46.
45.
KaleaAZSchmidtAMHudsonBI. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci2009; 116: 621–637.
46.
TripathiAKChawlaDBansalS,et al.Association of RAGE gene polymorphism with vascular complications in Indian type 2 diabetes mellitus patients. Diabetes Res Clin Pract2014; 103: 474–481.
47.
CaiZLiuNWangC, et al.Role of RAGE in Alzheimer’s disease. Cell Mol Neurobiol2016; 36: 483–495.
48.
McNairEQureshiMPrasadK,et al.Atherosclerosis and the hypercholesterolemic AGE-RAGE axis. Int J Angiol2016; 25: 110–116.
49.
FukamiKYamagishiSOkudaS. Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des2014; 20: 2395–2402.
50.
WinMTYamamotoYMunesueS, et al.Regulation of RAGE for attenuating progression of diabetic vascular complications. Exp Diabetes Res2012; 2012: 894605.
51.
MahajanNMahmoodSJainS,et al.Receptor for advanced glycation end products (RAGE), inflammatory ligand EN-RAGE and soluble RAGE (sRAGE) in subjects with takayasu’s arteritis. Int J Cardiol2013; 168: 532–534.
52.
LiGTangJDuY,et al.Beneficial effects of a novel RAGE inhibitor on early diabetic retinopathy and tactile allodynia. Mol Vis2011; 17: 3156–3165.
YuWYangJSuiW,et al.Association of genetic variants in the receptor for advanced glycation end products gene with diabetic retinopathy: a meta-analysis. Medicine (Baltimore)2016; 95: e4463.
55.
HamptonBMSchwartzSGBrantleyMAJr, et al. . Update on genetics and diabetic retinopathy. Clin Ophthalmol2015; 9: 2175–2193.
56.
KangPTianCJiaC. Association of RAGE gene polymorphisms with type 2 diabetes mellitus, diabetic retinopathy and diabetic nephropathy. Gene2012; 500: 1–9.
57.
JinHJiangDDingZ, et al.Association of four gene polymorphisms in Chinese Guangxi population with diabetic retinopathy in type 2 diabetic patients. BMC Ophthalmol2021; 21: 383.
58.
LiGYLiZBLiF, et al.Meta-analysis on the association of ALDH2 polymorphisms and type 2 diabetic mellitus, diabetic retinopathy. Int J Environ Res Public Health2017; 14: 165.
59.
O’BrienPJSirakiAGShangariN. Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol2005; 35: 609–662.
60.
YangKQiangDDelaneyS,et al.Differences in glyoxal and methylglyoxal metabolism determine cellular susceptibility to protein carbonylation and cytotoxicity. Chem Biol Interact2011; 191: 322–329.
61.
GouliopoulosNSiasosGMoschosMM, et al.Endothelial dysfunction and impaired arterial wall properties in patients with retinal vein occlusion. Vasc Med2020; 25: 302–308.
62.
WilkinsonCPFerrisFLIIIKleinRE, et al.Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology2003; 110: 1677–1682.
63.
MoschosMMChatziralliISioziouA,et al.Receptor of advanced glycation end products gene polymorphism and primary open-angle glaucoma. Ophthalmic Res2017; 58: 81–84.
64.
IshibashiTTaguchiAYamamotoY,et al.Evaluation of the use of self-reported facial flushing and ethanol patch test for ALDH2 genotypes. Nihon Arukoru Yakubutsu Igakkai Zasshi2010; 45: 464–476.
65.
XieJFenwickEKTaoukY, et al.Relative importance and contribution of risk factors for diabetic retinopathy and macular edema. J Diabetes Metab2014; 5: 2.
66.
SobrinLGreenTSimX, et al.Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the candidate gene association resource (CARe). Invest Ophthalmol Vis Sci2011; 52: 7593–7602.
67.
FanWYGuHYangXF,et al.Association of candidate gene polymorphisms with diabetic retinopathy in Chinese patients with type 2 diabetes. Int J Ophthalmol2020; 13: 301–308.
68.
CanningPGlennJVHsuDK,et al.Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res2007; 2007: 51837.
69.
MooreTCMooreJEKajiY, et al.The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci2003; 44: 4457–4464.
70.
ChenBHJiangDYTangLS. Advanced glycation end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes. Life Sci2006; 79: 1040–1048.
71.
BarileGRPachydakiSITariSR, et al.The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci2005; 46: 2916–2924.
72.
YamagishiSAmanoSInagakiY, et al.Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun2002; 290: 973–978.
73.
TarrJMKaulKChopraM,et al.Pathophysiology of diabetic retinopathy. ISRN Ophthalmol2013; 2013: 343560.
74.
HudsonBISticklandMHGrantPJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes1998; 47: 1155–1157.
75.
YuanDYuanDLiuQ. Association of the receptor for advanced glycation end products gene polymorphisms with diabetic retinopathy in type 2 diabetes: a meta-analysis. Ophthalmologica2012; 227: 223–232.
76.
NgZXKuppusamyURPohR, et al.Lack of association between Gly82Ser, 1704G/T and 2184A/G of RAGE gene polymorphisms and retinopathy susceptibility in Malaysian diabetic patients. Genet Mol Res2012; 11: 455–461.
77.
FlaxmanSRBourneRRAResnikoffS, et al.Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health2017; 5: e1221–e1234.
78.
ZhaoSLiTZhengB,et al.Nitric oxide synthase 3 (NOS3) 4b/a, T-786C and G894T polymorphisms in association with diabetic retinopathy susceptibility: a meta-analysis. Ophthalmic Genet2012; 33: 200–207.
79.
KatoNTakeuchiFTabaraY, et al.Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet2011; 43: 531–538.
80.
NoseJSaitoAKamataniN. Statistical analysis of the associations between polymorphisms within aldehyde dehydrogenase 2 (ALDH2), and quantitative and qualitative traits extracted from a large-scale database of Japanese single-nucleotide polymorphisms (SNPs). J Hum Genet2008; 53: 425–438.
81.
NakagawaTKajiwaraASaruwatariJ, et al.The combination of mitochondrial low enzyme-activity aldehyde dehydrogenase 2 allele and superoxide dismutase 2 genotypes increases the risk of hypertension in relation to alcohol consumption. Pharmacogenet Genomics2013; 23: 34–37.
82.
ChenYCPengGSTsaoTP,et al.Pharmacokinetic and pharmacodynamic basis for overcoming acetaldehyde-induced adverse reaction in Asian alcoholics, heterozygous for the variant ALDH2*2 gene allele. Pharmacogenet Genomics2009; 19: 588–599.
83.
LiHBorinskayaSYoshimuraK, et al.Refined geographic distribution of the oriental ALDH2*504Lys (nee 487Lys) variant. Ann Hum Genet2009; 73: 335–345.
84.
CerielloAIhnatMAThorpeJE. Clinical review 2: the “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications?J Clin Endocrinol Metab2009; 94: 410–415.
85.
SuzukiYMuramatsuTTaniyamaM, et al.Association of aldehyde dehydrogenase with inheritance of NIDDM. Diabetologia1996; 39: 1115–1118.
86.
IdewakiYIwaseMFujiiH, et al.Association of genetically determined aldehyde dehydrogenase 2 activity with diabetic complications in relation to alcohol consumption in Japanese patients with type 2 diabetes mellitus: the fukuoka diabetes registry. PLoS ONE2015; 10: e0143288.
87.
SuzukiYTaniyamaMMuramatsuT, et al.ALDH2/ADH2 Polymorphism associated with vasculopathy and neuropathy in type 2 diabetes. Alcohol Clin Exp Res2004; 28: 111S–116S.
